Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

Launched by HOSPITAL UNIVERSITARI VALL D'HEBRON RESEARCH INSTITUTE · Jul 10, 2024

Keywords

ClinConnect Summary

The MAMBO Phase I clinical trial is studying how different characteristics of migraine attacks can help predict how well a common migraine treatment called sumatriptan will work for patients. If you decide to participate, you will keep notes about your headaches before and after taking sumatriptan during four separate migraine episodes. This information will help researchers understand which traits make some people respond better to the treatment than others.

To join the study, you need to have a diagnosis of migraine (with or without aura) and experience fewer than eight migraine days each month. You should be able to read and understand the study instructions, and have access to the internet and an email address. However, if you are currently taking medication to prevent migraines, have certain medical conditions, or are pregnant or breastfeeding, you may not be eligible. If you participate, you can help contribute to important research that could improve migraine treatment for everyone.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Migraine with or without aura diagnosis according to ICHD-3 criteria
• • \<8 migraine days per month
• • Be able to read, write and understand instructions.
• • Have internet access and mail address
• • Signing of the informed consent
• Exclusion Criteria:
• • Active preventive treatment for migraine
• • Active medication with an effect over the central nervous system
• • Serious physical or psychiatric condition
• • Cardiovascular or hepatic disease
• • Pregnant or breastfeeding women
• • Any triptan contraindication
• • Severe migraine attacks without previous response to triptans or NSAIDs